Results 1 to 10 of about 12,575 (207)

Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. [PDF]

Nat Commun
Català-Moll F, Blázquez-Bondia C, Farré-Badia J, Torres F, Manzardo C, Bonfill E, Curran A, Domingo P, Podzamczer D, Force L, Falcó V, Parera M, Casadellà M, Miró JM, Noguera-Julian M, Paredes R, ADVANZ-4 MISTRAL investigators.   +16 more
europepmc   +1 more source

Maintain, not obtain: rethinking HIV care in sub-Saharan Africa in the era of dolutegravir. [PDF]

Front Public Health
Perno CF, Orlando S, Majid NA, Sangare H, Luanga R, Roccucci M, Silaghi LA, Sidumo Z, Brambilla D, Ceffa S, Guidotti G, Ciccacci F.   +11 more
europepmc   +1 more source

Impact of HAART therapy on cognitive function in patients with HIV: a systematic review of randomized control trial. [PDF]

Ann Med Surg (Lond)
Al Diab Al Azzawi M, Alhamed AM, Almajed H, Ahmed WA, Alshahrani NNA, Idris IS, Aldayhani OB, Fallatah F, Bedaiwi RH.   +8 more
europepmc   +1 more source

Analysis of Viral Blips Through Week 192 of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Studies of Doravirine-Based Regimens in Adults Living With Previously Untreated HIV-1. [PDF]

Open Forum Infect Dis
Molina JM, Orkin C, Paredes R, Xu ZJ, Su FH, Asante-Appiah E, Plank RM, Lahoulou R.   +7 more
europepmc   +1 more source

Laser Microinterferometry for API Solubility and Phase Equilibria: Darunavir as a Case Example. [PDF]

Pharmaceutics
Makarova V, Mandrik M, Antonov S.
europepmc   +1 more source

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV. [PDF]

Antimicrob Agents Chemother
Tsirizani L, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, McIlleron HM, Burger DM, Gibb DM, Colbers A, Denti P, Wasmann RE, CHAPAS-4 trial team.   +17 more
europepmc   +1 more source

Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens. [PDF]

AIDS
Marcelin AG, Soulie C, Wirden M, Gruber J, Prata Menezes N, Lim T, Barriere G, Descamps D, Charpentier C, Calvez V.   +9 more
europepmc   +1 more source

Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility: Evaluating genotypic HIV-2 drug resistance tools. [PDF]

PLOS Glob Public Health
Raugi DN, Nixon RS, Smith RA, Hawes SE, Diallo K, Diallo MB, Faye K, Diaw B, Sy MP, Sall F, Seydi M, Gottlieb GS, University of Washington-Senegal HIV-2 Study Group.   +12 more
europepmc   +1 more source

Resource Use and Cost Associated With Cardiovascular, Renal, Bone, and Neuropsychiatric Comorbidities in People With HIV in Spain. [PDF]

J Health Econ Outcomes Res
Ventayol P, Dueñas C, Martín C, Castro A, Citoler B, Vidal-Vilar N.   +5 more
europepmc   +1 more source

Mutational scan of self-cleavage by HIV-1 protease provides new views of a conformationally dynamic mechanism. [PDF]

J Virol
Nachum GS, Boucher JI, Flynn JM, Quansah P, Nachum S, Bolon DNA.   +5 more
europepmc   +1 more source